Intervention

GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting0

Common conditions4

Lead sponsors shown1

Clinical trials

1 shown

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2NCT05130255 · 2022-11-17

TERMINATED

Common conditions

High Risk Neuroblastoma1 Malignant Melanoma1 Sarcoma1 SCLC1

Leading sponsors

Y-mAbs Therapeutics1

Trial status mix

TERMINATED1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.